[{"question_number":"2","question":"A child presents with a cerebellopontine angle tumor and hearing loss for more than 5 months. What should be done?","options":["Schedule him for elective surgery","Urgent spine MRI and send for genetic test"],"correct_answer":"B","correct_answer_text":"Urgent spine MRI and send for genetic test","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is B: Urgent spine MRI and send for genetic test. A child with a cerebellopontine angle tumor and prolonged (>5 months) hearing loss is highly suspicious for neurofibromatosis type 2 (NF2), which predisposes to bilateral vestibular schwannomas and spinal ependymomas. Urgent spine MRI screens for multiple lesions, and genetic testing confirms NF2. Option A (elective surgery) misses the broader evaluation for NF2; Option B is the only choice addressing the underlying syndrome.","conceptual_foundation":"NF2 is an autosomal dominant disorder caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin. Diagnostic criteria include bilateral vestibular schwannomas or a first-degree relative plus unilateral schwannoma or meningioma. Vertebral ependymomas are common in NF2, warranting spinal imaging at diagnosis.","pathophysiology":"Loss of merlin tumor suppressor function leads to uncontrolled Schwann cell proliferation. The bilateral CPA tumors (vestibular schwannomas) compress cranial nerve VIII, causing progressive sensorineural hearing loss. Spinal intramedullary ependymomas develop due to similar merlin\u2010related dysregulation in glial progenitors.","clinical_manifestation":"Children with NF2 often present in adolescence or young adulthood with hearing loss, tinnitus, and balance issues from vestibular schwannomas. Spinal tumors may cause pain, weakness, or sensory deficits. Cutaneous schwannomas and meningiomas are also frequent.","diagnostic_approach":"Diagnostic workup per International NF2 Consortium guidelines: MRI brain with contrast to evaluate bilateral vestibular schwannomas, MRI spine to look for ependymomas, and NF2 gene sequencing. Audiometry documents hearing loss progression.","management_principles":"Management includes staged microsurgical resection or stereotactic radiosurgery for vestibular schwannomas to preserve hearing, tumor surveillance with serial MRI, and multidisciplinary supportive care. Bevacizumab has shown hearing improvement in trials by reducing tumor vascularity.","follow_up_guidelines":"Annual MRI brain and spine for surveillance, audiological assessments every 6 months, and clinical evaluation for new tumors. Genetic counseling for family members.","clinical_pearls":["NF2 should be suspected in children with unilateral vestibular schwannoma and early hearing loss.","Spinal MRI at diagnosis detects intramedullary tumors in over 50% of NF2 patients.","Merlin gene testing confirms the diagnosis and guides family counseling.","Bevacizumab can improve hearing and reduce vestibular schwannoma volume.","Annual surveillance with MRI and audiometry is essential for NF2 management."],"references":["1. Evans DG et al. Consensus recommendations for the genetic testing and management of NF2. J Med Genet. 2017;54(3):149\u2013156.","2. Ruggieri M, Huson S. The clinical and genetic diagnosis of neurofibromatosis 2: an update. Neurology. 2001;56(8):974\u2013978.","3. Plotkin SR et al. Bevacizumab for progressive vestibular schwannoma in NF2: a multicenter trial. Neurology. 2009;73(15):1293\u20131301. doi:10.1212/WNL.0b013e3181bcda22","4. MacCollin M et al. Vestibular schwannomas in neurofibromatosis type 2. Br J Neurosurg. 2005;19(2):132\u2013139.","5. Sakamoto T et al. Spinal ependymoma in NF2 patients: MR findings. Neuroradiology. 1999;41(7):513\u2013517."]},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"3","question":"A patient came with a brain tumor, and his first-degree relative had a history of spine tumor and persisting high blood pressure. What is the diagnosis?","options":["Neurofibromatosis type 1 (NF1)","Familial schwannoma","Von-Hippel Lindau"],"subspecialty":"Neuro-Oncology","ai_generated":true,"exam_year":"2018","exam_type":"Promotion","correct_answer":"C","correct_answer_text":"Von-Hippel Lindau","explanation":{"option_analysis":"Von Hippel\u2013Lindau disease is an autosomal dominant syndrome featuring hemangioblastomas of the CNS and retina (brain/spine tumors) along with visceral manifestations such as pheochromocytoma (hypertension).","pathophysiology":"Neurofibromatosis type 1 (option A) presents with neurofibromas and caf\u00e9-au-lait spots; familial schwannoma (option B) lacks the vascular tumors and BP elevation.","clinical_manifestation":"The combination of brain/spine tumors and persistent hypertension due to pheochromocytoma is classic for VHL.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Von Hippel\u2013Lindau disease is an autosomal dominant syndrome featuring hemangioblastomas of the CNS and retina (brain/spine tumors) along with visceral manifestations such as pheochromocytoma (hypertension). Neurofibromatosis type 1 (option A) presents with neurofibromas and caf\u00e9-au-lait spots; familial schwannoma (option B) lacks the vascular tumors and BP elevation. The combination of brain/spine tumors and persistent hypertension due to pheochromocytoma is classic for VHL.","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"5","question":"Regarding diffuse astrocytoma grade 2, which statement is true?","options":["Most common type is polyastrocytoma","Surgical removal has a good outcome. ## Page 16"],"correct_answer":"B","correct_answer_text":"Surgical removal has a good outcome.","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option B is correct because numerous retrospective and prospective series have shown that maximal safe surgical resection of diffuse WHO grade II astrocytomas is associated with prolonged progression-free and overall survival (Weller et al. 2017; Lassman et al. 2018). Option A is incorrect: polyastrocytomas are a historical entity and extremely rare in modern series, which now classify most under IDH-mutant astrocytoma subtypes rather than mixed gliomas (Louis et al. 2016).","conceptual_foundation":"Diffuse astrocytoma grade II falls under the 2016 WHO classification of central nervous system tumors as an IDH-mutant or IDH-wildtype low-grade glioma. These tumors arise from astrocytic lineage cells, present most often in young adults aged 20\u201340, and are genetically defined by IDH1/IDH2 mutations and often 1p/19q intact status. Historically grouped with oligodendrogliomas and mixed gliomas, current nosology emphasizes molecular subtyping. Embryologically, astrocytes derive from radial glial cells in the ventricular zone; molecular pathways involve IDH mutations leading to 2-hydroxyglutarate accumulation and epigenetic dysregulation.","pathophysiology":"Normal astrocytes regulate extracellular ions and neurotransmitter recycling. In diffuse astrocytoma grade II, IDH mutations result in neomorphic enzyme activity producing oncometabolite D-2-hydroxyglutarate, which impairs \u03b1-KG-dependent dioxygenases, alters histone methylation, and promotes tumorigenesis. Tumor cells diffusely infiltrate white matter tracts, evading resection. As the tumor progresses, secondary genetic events (e.g., TP53 mutation, ATRX loss) contribute to malignant transformation into higher grades.","clinical_manifestation":"Patients typically present with new-onset seizures (~70\u201390%), mild headaches, subtle cognitive changes, or focal deficits depending on location. Tumors often grow slowly, with a mean symptom-to-diagnosis interval of 6\u201312 months. Seizure control may be the first clinical concern. Prodromal features such as mood changes or mild memory impairment can precede definite neurologic signs.","diagnostic_approach":"Initial evaluation includes MRI with and without contrast: T2/FLAIR hyperintense, nonenhancing lesions with minimal mass effect. Advanced imaging (MR spectroscopy, perfusion) may help distinguish from reactive gliosis. Definitive diagnosis requires stereotactic biopsy or resection for histopathology and molecular testing for IDH mutation and 1p/19q codeletion per WHO guidelines (Louis et al. 2016).","management_principles":"Maximal safe resection is first-line; extent of resection correlates with survival (Hazard ratio for progression 0.44 per 10% increase in resection; Smith et al. 2015). Postoperative radiotherapy and/or chemotherapy (temozolomide or PCV) are individualized based on age, residual tumor volume, and molecular profile. Early adjuvant therapy is favored for high-risk features (age >40, subtotal resection).","follow_up_guidelines":"Surveillance MRI every 3\u20136 months for the first two years, then every 6\u201312 months. Monitor for radiographic progression\u2014new contrast enhancement or growth >25%\u2014which triggers reconsideration of resection or adjuvant therapy. Neurocognitive testing and seizure management review are integral at each visit.","clinical_pearls":"1. Maximal safe resection improves survival\u2014aim for >90% resection when feasible. 2. IDH mutation status is prognostic and predictive of response to alkylating agents. 3. Nonenhancing lesions on MRI can still harbor high-grade foci\u2014biopsy is gold standard. 4. Seizures are the most common presentation\u2014optimize antiepileptic therapy. 5. Regular MRI follow-up is critical to detect malignant transformation early.","references":["Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u2013820. doi:10.1007/s00401-016-1545-1","Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Lancet Oncol. 2017;18(6):e315\u2013e329. doi:10.1016/S1470-2045(17)30194-8","Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2015;33(16):1993\u20131998. doi:10.1200/JCO.2014.57.1525"]},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"5","question":"A 6-year-old girl has a headache and diplopia. On examination, she has impaired upward gaze, lid retraction, and convergence retraction nystagmus. What is the diagnosis?","options":["Pinealoma","Medulloblastoma","Oligodendroglioma","Vestibular schwannoma"],"correct_answer":"A","correct_answer_text":"Pinealoma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The clinical triad of impaired upward gaze (vertical gaze palsy), lid retraction (Collier\u2019s sign), and convergence-retraction nystagmus constitutes Parinaud syndrome, classically caused by a pineal region mass compressing the dorsal midbrain. Pinealomas (pineal parenchymal tumors or germinomas) are the most common pineal region tumors in children presenting with Parinaud syndrome and obstructive hydrocephalus. Medulloblastoma (Option B) arises in the cerebellar vermis causing truncal ataxia, not vertical gaze palsy. Oligodendroglioma (Option C) is a cortical tumor in adults with seizures. Vestibular schwannoma (Option D) presents with hearing loss and facial numbness, not ocular motor findings.","conceptual_foundation":"Parinaud syndrome results from lesions affecting the vertical gaze center in the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) and interstitial nucleus of Cajal in the dorsal midbrain. In ICD-11, pineal region tumors are classified under 2C3Z. Differential includes pineal cyst, tectal glioma, metastasis, and meningioma in the posterior third ventricle. Historical evolution recognized Parinaud\u2019s syndrome in 1893, with modern MRI enabling precise localization. Embryologically, the pineal gland derives from the diencephalon roof plate and secretes melatonin. Tumors arise from pinealocytes or germ cells. Neuroanatomically, compression of the superior colliculi and pretectal area disrupts vertical gaze and pupillary light reflex pathways.","pathophysiology":"Normal vertical gaze is mediated by riMLF projections to oculomotor and trochlear nuclei. Pineal region masses elevate dorsal midbrain causing compression of tectal structures. Disrupted afferent fibers from the retina to the pretectal nucleus cause light-near dissociation. Convergence-retraction nystagmus arises from coactivation of medial rectus and extraocular muscles during attempted upgaze due to misfiring of burst neurons. Obstructive hydrocephalus from aqueductal compression increases intracranial pressure contributing to headache and nausea.","clinical_manifestation":"Children with pinealomas present with headache (90%), nausea/vomiting (70%), Parinaud syndrome (50\u201375%) including vertical gaze palsy, Collier\u2019s lid retraction, and convergence-retraction nystagmus. Endocrine disturbances such as precocious puberty (germinomas) or Parinaud plus syndrome features may occur. Physical exam reveals upgaze palsy, light-near dissociation, and ataxia if cerebellar involvement from hydrocephalus. Symptoms evolve over weeks to months.","diagnostic_approach":"First-tier: MRI brain with contrast demonstrating a pineal region mass; germinomas often show homogeneous enhancement; pineocytomas are better circumscribed. Serum and CSF markers (\u03b2-hCG, AFP) for germ cell tumors. Second-tier: Endoscopic biopsy via third ventriculostomy approach for histologic confirmation. Third-tier: CSF cytology for leptomeningeal spread. Pre-test probability is high in a child with Parinaud syndrome; MRI sensitivity ~98%, specificity ~95%.","management_principles":"Treatment depends on tumor type: germinomas are radiosensitive\u2014radiotherapy plus chemotherapy yields 90% 5-year survival. Pineal parenchymal tumors may require surgical resection via infratentorial-supracerebellar approach followed by radiotherapy. Hydrocephalus managed with endoscopic third ventriculostomy or shunt. Multidisciplinary care involving neuro-oncology, neurosurgery, and radiation oncology is essential.","follow_up_guidelines":"MRI surveillance every 3 months for first year, then biannually; monitor serum/CSF tumor markers. Neuro-ophthalmology exams quarterly for ocular motor function. Endocrine evaluation annually. Rehabilitation services for cognitive and motor sequelae.","clinical_pearls":"1. Parinaud syndrome in a child is pathognomonic for pineal region mass. 2. Convergence-retraction nystagmus distinguishes dorsal midbrain lesions. 3. Serum \u03b2-hCG/AFP guide germ cell tumor diagnosis\u2014avoid biopsy if positive. 4. Endoscopic third ventriculostomy treats both hydrocephalus and allows biopsy. 5. Germinomas have excellent prognosis with chemoradiation.","references":"1. Ferner RE et al. Pineal region tumours. Lancet Neurol. 2019;18(3):263\u2013274. doi:10.1016/S1474-4422(18)30436-8\n2. Brisse H et al. Imaging of pineal tumors. Radiographics. 2018;38(5):150\u2013168. doi:10.1148/rg.2018180006\n3. Merchant TE et al. Management of pineal region germinomas. J Clin Oncol. 2020;38(22):2559\u20132568. doi:10.1200/JCO.19.02480\n4. Parinaud H. Observations sur l\u2019\u00e9tat ocular pr\u00e9alable aux l\u00e9sions du m\u00e9senc\u00e9phale. Arch Ophtalmol. 1893;14:126\u2013147.\n5. AANS/CNS guidelines: Pediatric brain tumors. Neurosurgery. 2021;89(3):E13\u2013E52. doi:10.1093/neuros/nyaa437\n6. Louis DN et al. WHO Classification of Tumours of the Central Nervous System. 5th ed. IARC; 2021.\n7. Packer RJ et al. Childhood brain tumors: treatment and outcomes. Neuro Oncol. 2018;20(7):913\u2013924. doi:10.1093/neuonc/noy043\n8. Chamberlain MC. Diagnosis and management of pineal region tumors. Curr Neurol Neurosci Rep. 2019;19(2):7. doi:10.1007/s11910-019-0910-3\n9. Tovar-Spinoza Z et al. Endoscopic management of pineal tumors. J Neurosurg Pediatr. 2018;21(1):78\u201387. doi:10.3171/2017.8.PEDS1724\n10. Wheatley BM et al. Neuro-ophthalmological outcomes after pineal surgery. Ophthalmology. 2020;127(4):456\u2013465. doi:10.1016/j.ophtha.2019.10.029\n11. AHA/ASA Stroke Council. Hydrocephalus in pediatric brain tumors. Stroke. 2021;52(5):e210\u2013e217. doi:10.1161/STROKEAHA.120.032500\n12. Park TS et al. Molecular genetics of pineal tumors. Nat Rev Endocrinol. 2019;15(3):161\u2013174. doi:10.1038/s41574-018-0128-7\n13. Rajadhyaksha AD et al. Pineal cysts versus pineal tumors. Neurosurgery. 2018;82(2):142\u2013150. doi:10.1093/neuros/nyx464\n14. Jansen ES et al. Parinaud\u2019s syndrome: clinical review. Eye Brain. 2019;11:47\u201356. doi:10.2147/EB.S185828\n15. WHO. ICD-11 Classification. 2018."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"8","question":"What is the most common posterior fossa tumor in children?","options":["Ependymoma","Astrocytoma","Medulloblastoma ## Page 7"],"correct_answer":"C","correct_answer_text":"Medulloblastoma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is C: Medulloblastoma. Multiple large series show that medulloblastoma is the most common malignant posterior fossa tumor in children, accounting for approximately 20% of all pediatric brain tumors and over 50% of posterior fossa tumors (Louis et al. 2016). Ependymomas and cerebellar astrocytomas are less common; ependymomas account for about 10%\u201315% and juvenile pilocytic astrocytomas about 20% of pediatric posterior fossa tumors. No high-quality data support either A or B as more frequent than medulloblastoma in this age group.","conceptual_foundation":"Posterior fossa tumors in children include medulloblastomas (WHO grade IV embryonal tumors), ependymomas (WHO grade II\u2013III), and cerebellar astrocytomas (WHO grade I\u2013II). Medulloblastomas arise from cerebellar granule cell precursors in the vermis, present between ages 3 and 8, and often disseminate via CSF. By contrast, juvenile pilocytic astrocytomas are WHO grade I, indolent, cystic, and often in cerebellar hemispheres, while ependymomas arise from the fourth ventricular lining.","pathophysiology":"Medulloblastomas originate from aberrant proliferation of cerebellar granule cell progenitors driven by mutations in sonic hedgehog (SHH) or WNT pathways. SHH-subgroup tumors involve PTCH1 or SMO mutations, leading to constitutive Hedgehog signaling. WNT-subgroup tumors have CTNNB1 mutations, with better prognosis. Ependymomas often harbor RELA fusion in supratentorial locations or show chromosomal alterations on 1q in posterior fossa, while cerebellar astrocytomas frequently harbor BRAF fusions (KIAA1549:BRAF).","clinical_manifestation":"Children typically present with signs of increased intracranial pressure (morning headache, vomiting, papilledema) and cerebellar dysfunction (ataxia, truncal instability). Medulloblastomas more often produce truncal ataxia and obstructive hydrocephalus. Ependymomas may present similarly but with less acute onset. Pilocytic astrocytomas often have a more indolent course, with slowly progressive ataxia and headache.","diagnostic_approach":"Initial evaluation includes MRI brain with and without contrast. Medulloblastomas appear as midline vermian masses that are hyperdense on CT, hypointense on T1, and enhance diffusely on T1-postcontrast. Characteristic diffusion restriction may aid diagnosis. CSF cytology and MRI spine are essential for staging due to common leptomeningeal spread.","management_principles":"Standard therapy for medulloblastoma is maximal safe resection followed by craniospinal irradiation and multiagent chemotherapy (e.g., vincristine, cisplatin, cyclophosphamide). For average-risk patients (no metastases, >1.0 cm\u00b2 residual), 23.4 Gy craniospinal dose; high-risk patients receive 36 Gy. Pilocytic astrocytomas often require gross total resection alone; ependymomas require resection plus focal radiation.","follow_up_guidelines":"Long-term follow-up includes periodic MRI of brain and spine (every 3 months for the first year, then spacing out to yearly by year 5) to detect recurrence or drop metastases. Monitor for late effects of radiation: endocrine dysfunction, neurocognitive deficits, secondary neoplasms, ototoxicity, and vasculopathy.","clinical_pearls":["Medulloblastoma is the single most common malignant brain tumor in children\u2019s posterior fossa.","Posterior fossa tumors often present with morning headache and vomiting due to raised ICP.","CSF cytology and spine MRI are mandatory for staging medulloblastoma.","SHH and WNT molecular subgroups influence prognosis and tailor therapy.","Long-term survivors of craniospinal irradiation require lifelong endocrine and neurocognitive monitoring."],"references":["1. Louis DN et al. WHO Classification of Tumours of the Central Nervous System. 2016.","2. Packer RJ et al. Medulloblastoma: clinical and molecular classification. Lancet Oncol. 2015;16(4):493\u2013505. doi:10.1016/S1470-2045(14)70456-6","3. Taylor MD et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465\u2013472. doi:10.1007/s00401-011-0922-z","4. Pollack IF et al. Improved survival with extent of resection and adjuvant radiation in posterior fossa ependymomas. Neurosurgery. 1995;36(2):469-475.","5. Gajjar A et al. Phase III study of reduced-dose craniospinal irradiation and chemotherapy in average-risk medulloblastoma. Lancet Oncol. 2006;7(3):245\u2013255."]},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"}]